Katherine Karakasis

Katherine Karakasis

UNVERIFIED PROFILE

Are you Katherine Karakasis?   Register this Author

Register author
Katherine Karakasis

Katherine Karakasis

Publications by authors named "Katherine Karakasis"

Are you Katherine Karakasis?   Register this Author

18Publications

568Reads

33Profile Views

Resisting RECIST-Uniformity Versus Clinical Validity.

Int J Gynecol Cancer 2017 10;27(8):1619-1627

*Auckland City Hospital, Auckland, New Zealand; †Prince of Wales Hospital, Sydney, Australia; ‡Princess Margaret Cancer Centre, Toronto, Ontario Canada; §Department of Radiation Oncology, Loyol University, Chicago, IL; ‖Instituto Valenciano de Oncologia, Valencia, Spain; ¶Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Paris, France; and #Gynecologic Group Intergroup, Kingston, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000001062DOI Listing
October 2017

Updates and current challenges in microRNA research for personalized medicine in ovarian cancer.

Expert Opin Biol Ther 2017 08 22;17(8):927-943. Epub 2017 Jun 22.

a Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre , University Health Network , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2017.1340935DOI Listing
August 2017

Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.

J Clin Oncol 2017 Apr 21;35(11):1240-1249. Epub 2017 Feb 21.

Stephanie Lheureux, Jeff P. Bruce, Julia V. Burnier, Katherine Karakasis, S.Y. Cindy Yang, Rene Quevedo, Tiantian Li, Mark Dowar, Valerie Bowering, Trevor J. Pugh, and Amit M. Oza, Princess Margaret Cancer Centre; Stephanie Lheureux, Patricia A. Shaw, Blaise A. Clarke, S.Y. Cindy Yang, Rene Quevedo, Trevor J. Pugh, and Amit M. Oza, University of Toronto; Patricia A. Shaw and Blaise A. Clarke, University Health Network, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3677DOI Listing
April 2017

Current and emerging treatment options in the management of advanced ovarian cancer.

Expert Opin Pharmacother 2016 Jun 16;17(8):1063-76. Epub 2016 Mar 16.

a Division of Medical Oncology and Hematology, Princess Margaret Hospital , University of Toronto , Toronto , Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2016.1159295DOI Listing
June 2016

Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention.

Front Oncol 2016 11;6:119. Epub 2016 May 11.

Drug Development Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2016.00119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862980PMC
May 2016

New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?

Curr Oncol Rep 2016 Apr;18(4):23

Department of Medicine, Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-016-0507-zDOI Listing
April 2016

Discrepancies in drug approvals: A global dilemma.

Cancer 2015 Sep 16;121(18):3360-1. Epub 2015 Jun 16.

Division of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29484DOI Listing
September 2015

Ovarian cancer treatment: The end of empiricism?

Cancer 2015 Sep 10;121(18):3203-11. Epub 2015 Jun 10.

Division of Medical Oncology and Hematology, Bras Family Drug Development Program, Princess Margaret Cancer Center, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744728PMC
September 2015

Safety evaluation of olaparib for treating ovarian cancer.

Expert Opin Drug Saf 2015 Aug 8;14(8):1305-16. Epub 2015 Jun 8.

University of Toronto, Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Drug Development Program , 610 University Avenue, Toronto, Ontario , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14740338.2015.1045875DOI Listing
August 2015

Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: Accuracy of assessment and potential surrogate marker for prevention.

Gynecol Oncol 2015 Aug 10;138(2):235-7. Epub 2015 Jun 10.

Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2015.06.014DOI Listing
August 2015

Outcomes and endpoints in trials of cancer treatment: the past, present, and future.

Lancet Oncol 2015 Jan 29;16(1):e32-42. Epub 2014 Dec 29.

Princess Margaret Cancer Centre, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(
Web Search
http://dx.doi.org/10.1016/S1470-2045(14)70375-4DOI Listing
January 2015

Outcomes and endpoints in cancer trials: bridging the divide.

Lancet Oncol 2015 Jan 29;16(1):e43-52. Epub 2014 Dec 29.

University of Toronto Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70380-8DOI Listing
January 2015

Uncovering a link between a plastid translocon component and rhomboid proteases using yeast mitochondria-based assays.

Plant Cell Physiol 2007 Apr 27;48(4):655-61. Epub 2007 Feb 27.

Department of Biology, Queen's University, Kingston, Ontario, Canada K7L 3N6.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/pcp/pcm031DOI Listing
April 2007